In view of the above findings, cPLA2 and sPLA2 are two valuable therapeutic targets, hence targeting the PLA2 enzyme mediator herbal products (such as PG201, Boerhaavia diffusa, Salvia miltiorrhiza extract and HMBA) development is likely to be a potential therapeutic strategy during the process of RA treatment. This evidence concerns the gene PLA2G6 and rheumatoid arthritis.